| | |
| Clinical data | |
|---|---|
| Trade names | Ovalyse |
| Other names | TAP-031; U-69689; 9-(N-Ethyl-L-prolinamide)-10-deglycinamide; 9-(N)-Et-ProNH2-10-des-GlyNH2-LHRH; Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-NHEt |
| Drug class | GnRH analogue; GnRH agonist; Antigonadotropin |
| ATCvet code | |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.164.570 |
| Chemical and physical data | |
| Formula | C55H76N16O12 |
| Molar mass | 1153.313 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fertirelin, or fertirelin acetate, sold under the brand name Ovalyse, is a gonadotropin-releasing hormone agonist (GnRH agonist) which has been marketed in the United Kingdom and Austria. [1] [2] [3] It may no longer be available. [4] Fertirelin has been used in veterinary medicine. [2] It may have been used in the treatment of sex hormone-dependent conditions and infertility in women. [3] The drug was first introduced in 1981 in Japan to treat various kinds of ovarian failure in cattle. [5] Fertirelin is a synthetic peptide and GnRH analogue. [1] [2] It is used as the acetate salt. [2]